Daunorubicin for Younger Adults with Acute Myeloid Leukemia

Abstract

Despite considerable advances during the past 20 years in the diagnostic and prognostic stratification of adult acute myeloid leukemia (AML) — as well as numerous efforts to improve induction therapy — the standard induction treatment remains the “7+3” regimen of cytarabine for 7 days plus three once-daily doses of an anthracycline. To assess the effects of anthracycline dose intensification in AML induction therapy, investigators conducted a randomized phase III trial of …